People default image

Michael Patrone

Partner
About

Michael's practice focuses on all aspects of mergers and acquisitions (M&A). He represents domestic and foreign entities, boards of directors, special board committees, private equity sponsors, and investment banks in public and private company transactions, tender offers, joint ventures, reverse mergers, transactions with special purpose acquisition companies (SPACs), cross-border transactions, private investment in public equity (PIPEs), minority investments, shareholder activism and governance disputes, financial advisory matters, and general corporate matters.

Michael's clients span a wide range of industries, including life sciences, biotech, biopharma and pharmaceuticals, technology, software and software as a service (SaaS), healthcare, financial services, digital currency and blockchain, digital infrastructure, and telecommunications. Michael also represents top-tier private equity and venture capital funds, hedge funds, family offices, and multi-strategy investors, as well as their respective portfolio companies, in acquisitions, sales, and financings. Additionally, he represents leading financial institutions with their work on some of the world's largest M&A transactions.

Bar admissionsFloridaNew York
Education
  • J.D., Harvard Law School
    cum laude
  • M.S., Accounting, University of Florida
    Beta Alpha Psi
  • B.S., Accounting,University of Florida

EXPERIENCE

  • SpringWorks Therapeutics, Inc. with its USD3.9 billion sale to Merck KGaA
  • Semler Scientific, Inc. with its sale to Strive, Inc. in an all-stock transaction that valued Semler Scientific at approximately USD1.34 billion and was the first merger of two publicly traded Bitcoin companies
  • Zuora, Inc. with its USD1.7 billion sale to Silver Lake and GIC Pte. Ltd.
  • MyoKardia, Inc. with its USD13.1 billion sale to Bristol-Myers Squibb Company
  • Biocon Biologics Limited with its acquisition of Viatris, Inc.'s biosimilars business for cash and stock valued at approximately USD3.335 billion
  • Twilio, Inc. with its acquisition of SendGrid, Inc. in an all-stock transaction valued at approximately USD3 billion
  • Foundation Medicine, Inc. with its USD5.3 billion sale to Roche
  • PTC, Inc. in its strategic partnership Rockwell Automation, Inc. and in securing a USD1 billion equity investment
  • A virtual imaging technology company with its USD218 million sale to a leading manufacturer of display technologies
  • Investors in Enfusion, Inc. with Enfusion's USD1.5 billion sale to Clearwater Analytics Holdings, Inc. and related USD30 million tax receivable agreement (TRA) buyout
  • Investors in Signal Sciences Corporation with Signal Sciences' USD775 million sale to Fastly, Inc.
  • Clearwater Analytics with its TRA buyout
  • Lumine Group, Inc. with its acquisition of Synchronoss Technologies, Inc.
  • Cycle Group Holdings Limited with its acquisition of Applied Therapeutics, Inc.
  • Evergreen Coast Capital with its USD1.6 billion take-private acquisition of Gigamon, Inc.
  • A leading multinational information technology company in the USD7 billion spin-off and merger of its enterprise services business with a multinational IT services corporation to form DXC Technology Company
  • A medical technology company with the sale of its blood screening business for USD1.85 billion to Grifols S.A.
  • Diamond Resorts International, Inc. with its USD2.2 billion sale to Apollo Management
  • Marriott International, Inc. with its USD12.2 billion acquisition of a global hospitality company
  • Shire plc with its abandoned USD54.8 billion sale to AbbVie, Inc.
  • Bertelsmann SE & Co. KGaA and Random House in the merger of Random House with Penguin Publishing House
  • Dalian Wanda Group with its USD2.6 billion acquisition of AMC Entertainment Holdings, Inc.
     
SPAC transactions and reverse mergers
  • Kronos Bio, Inc. with its strategic review process and take-private by Concentra Biosciences, LLC
  • Magenta Therapeutics, Inc. with its business combination with Dianthus Therapeutics, Inc.
  • Pear Therapeutics, Inc. with its business combination with a SPAC Thimble Point
  • Acquisition Corporation in a transaction valued at approximately USD1.6 billion
  • Markforged, Inc. with its business combination with a SPAC in a transaction valued at approximately USD2.1 billion
  • Alpha Healthcare Acquisition Corporation with its business combination with Humacyte, Inc. in a transaction valued at approximately USD1.1 billion
  • Cano Health, LLC with its business combination with SPAC Jaws Acquisition Corporation in a transaction valued at approximately USD5.9 billion
  • Existing investors in an Billtrust with Billtrust's business combination with SPAC South Mountain Merger Corporation in a transaction valued at approximately USD2.5 billion
  • Immatics N.V. with its business combination with SPAC Arya Sciences Acquisition Corporation in a transaction valued at approximately USD1 billion
  • Lead Edge Growth Opportunities, Ltd. with its de-SPAC process
  • Investors in Ginkgo Bioworks, Inc.'s business combination with SPAC Soaring Eagle Acquisition Corporation  in a transaction valued at approximately USD17.5 billion
  • Investors in a radiopharmaceutical company's business combination with a SPAC in a transaction valued at approximately USD924 million
     
Financial institutions
  • Marathon Oil Corporation's USD22.5 billion sale to ConocoPhillips
  • Envestnet, Inc.'s USD4.5 billion sale to Bain Capital
  • Royalty Pharma plc's USD1.1 billion acquisition of its external manager, RP Management, LLC
  • Telesat Corporation's USD5 billion low-Earth orbit satellite project
  • Wisconsin Energy Corporation's USD9.1 billion acquisition of Integrys Holding, Inc.

Publications

Michael is a frequent speaker on matters related to corporate governance, M&A, SPACs, corporate finance, and securities law.

Prior Experience

Prior to joining DLA Piper, Michael was a partner in the Technology/Life Sciences and Private Equity business units, as well as a member of the Public M&A/Corporate Governance practice, for a major AmLaw 200 international law firm.

Memberships and Affiliations

  • Executive Board Member, Harvard Business Law Review
  • Executive Board Member, Harvard Journal of Law & Public Policy